The p53 master regulatory network provides for the stress-responsive direct control of a vast number of genes in humans that can be grouped into several biological categories including cell-cycle control, apoptosis and DNA repair. Similar to other sequence-specific master regulators, there is a matrix of key components, which provide for variation within the p53 master regulatory network that include p53 itself, target response element sequences (REs) that provide for p53 regulation of target genes, chromatin, accessory proteins and transcription machinery. Changes in any of these can impact the expression of individual genes, groups of genes and the eventual biological responses. The many REs represent the core of the master regulatory network. Since defects or altered expression of p53 are associated with over 50% of all cancers and greater than 90% of p53 mutations are in the sequence-specific DNA-binding domain, it is important to understand the relationship between wildtype or mutant p53 proteins and the target response elements. In the words of the legendary detective Sherlock Holmes, it is 'Elementary, my dear Mr. Watson.'
There have been two approaches to the identification of p53-binding elements. One involves the iterative enrichment of sequences that could bind p53 in vitro, and another relies on cloning of random human sequences into a transcription reporter vector in yeast cells that constitutively express high levels of p53 (Figure 1a ), followed by alignment and pattern search on the transcriptionally active sequences (el-Deiry et al., 1992; Tokino et al., 1994) . Further experimental validation of defined candidate sequences generally relied on competitive gel shift analysis, DNA fingerprinting or on gene reporter assays in transiently transfected mammalian cells (Freeman et al., 1994; Thukral et al., 1995; Wang et al., 1995; Nagaich et al., 1997 Nagaich et al., , 1999 McLure and Lee, 1998; Resnick-Silverman et al., 1998) . On the basis of these approaches, a consensus sequence was developed over 10 years ago consisting of two 10-base dimers separated by a 0-13 base spacer (n): RRRCWWGYYY (n) RRRCWWGYYY, where R is purine, Y is pyrimidine and W is A or T (el-Deiry et al., 1992; Funk et al., 1992) . This consensus sequence and related nucleotide position weight matrices (PWM) have been adopted as the standard for identifying potential p53 targets using computational approaches (Tokino et al., 1994; Wang et al., 2001; Hoh et al., 2002; Liu et al., 2004; Miled et al., 2005) . Although this consensus is already quite degenerate, nearly all established human response element sequences (REs) have at least one mismatch.
Recently, the p53 consensus sequence received further support using a very different approach, described by Wei et al. (2006) . They developed a novel, genome-wide chromatin immunoprecipitation (ChIP) method and an improved sequencing strategy for analysing DNA sequences that can directly bind p53 in human cells that are exposed to 5-fluoruracil, a base analog that efficiently induces p53. Over 500 p53-binding loci in the human genome were identified from the analysis of B60 000 p53-ChIP fragments providing greater definition to the above consensus resulting in a refined matrix of nucleotide probabilities at each position. Many established p53 target REs were not retrieved under the experimental conditions used, suggesting that either the sites were not accessible to p53 or the crosslinking agent or p53 occupancy at those sites was below the detection threshold (Wei et al., 2006) . For the individual dimer-binding sites, the more common RRR and YYY are AGA and (C/T)CC, respectively, and there is strong preference for CATG as the central four bases. Those results predicted AGACATG(C/T)CC as the strongest consensus under the commonly held assumption that nucleotide frequencies at any given position can be independently related to the DNA-binding affinity of a transcription factor to the complete RE (MacIsaac and Fraenkel, 2006) . However, complex protein-DNA mutual allosteric modifications, particularly when a transcription factor (TF) assembles on target sites as a multimer, such as in the case of p53 (Nagaich et al., 1997; McLure and Lee, 1998) , can generate dependencies between nucleotides at different positions of the consensus thus limiting the predictions based on PWM.
Although these various methods identify sequences that can bind p53, they do not necessarily address the range of sequences that could qualify as functional binding sites in terms of the ability of p53 to both bind and modulate transcription of an associated gene, nor do they address the dynamics of such functional interactions at binding sites. In the various screens that were developed, there was a preference for sequences that could be considered as strong binders. Each of these screens represents a different endpoint assessment of p53 Figure 1 Yeast as an in vivo test tube to assess the transactivation capacity of p53 towards various response elements (REs). (a) Constitutive expression of p53. Presented are generic, yeast-based systems for assessing p53 functional status under conditions where the p53 cDNA is constitutively expressed from a moderate to strong promoter such as ADH1 on a selectable, low copy plasmid vector or as a construct integrated into the chromosome. The p53 is considered to form dimer molecules, which are then proposed to interact with individual RE sequences to form tetramers. The different REs (i.e., RE x1 , RE x2 , RE x3 , etc.), which can be derived from human p53 regulated genes, are present in separate isogenic strains that differ only by the RE sequences. The REs replace the upstream activating sequences of a minimal promoter (i.e., cytochrome c) that regulates the expression of a reporter that allows growth on deficient media (i.e., HIS3 and URA3) or a color reporter (i.e., ADE2, and bgalactosidase) or a quantitative reporter (i.e., green fluorescent protein (GFP), Ds-Red or firefly luciferase). Transactivation of the reporter gene is p53-dependent and requires interaction with the RE sequence. Multiple yeast strains containing different RE sequences can be used to assess how specific deviations from the consensus sequence affect p53 transactivation, as well as provide functional fingerprints of the transactivation capacity of mutant p53s. Although this system is useful in discriminating between p53 alleles with loss or altered-function, it is limited in its ability to identify variant p53 alleles that have subtle phenotypic alterations, owing to the high levels of p53 expression. (b) Rheostatable promoter system to quantitatively address p53 transactivation capacity. The p53 gene is integrated and placed under the control of a rheostatable GAL1 promoter that provides for highly controlled expression of p53 protein. When cells are grown on glucose, the GAL1 promoter is repressed. On raffinose the GAL1 promoter is de-repressed but not induced, resulting in a basal level of expression. Addition of galactose induces p53 expression. Depending on the amount of galactose added, the expression can be varied over a 100-fold range. This feature provides for analysis of transactivation by p53 from individual REs at various p53 expression levels and it also enables transactivation to be assessed for various p53 mutants under conditions of low expression. As described in the text, several mutants differ from wild type only when the expression is low. This system has been modified recently such that RE::reporters are created in one set of haploid strains and various p53 mutants are created in another set of haploids of opposite mating type (Jordan, Inga and Resnick, unpublished) . Following mating, p53 induced transcription of the various RE::reporters can be assessed. The diploid system allows for the rapid assessment of the transactivation potential for many p53 variants towards many individual RE sequences at various levels of p53 expression. (c) Qualitative color assay on petri plates to assess p53 transactivation. The ADE2 phenotypic color assay (RE::ADE2) determines the ability of p53 variants to transactivate from specific REs in stationary cells on plates. In the absence of the ADE2 gene product, cells growing on minimal medium with just a small amount of adenine accumulate a red pigment. With increased p53 transactivation from the RE, cells are able to complete the adenine biosynthesis and the red pigment is no longer accumulated. Hence, colony pigmentation is dependent on the ability of p53 to transactivate from a specific RE sequence. If p53 (wild type or mutant) is capable of strongly transactivating from a RE, colonies are large in size and white, whereas if p53 is not able to transactivate from a RE, colonies are smaller and red. Inducible expression of p53 under the rheostatable GAL1 promoter allows for p53-transactivation capacity to be assessed at variable levels of protein expression. Therefore, the range of pigmentation (pink to white) correlates with the extent of p53 transactivation from a particular RE. To compare the responsiveness of various REs to p53 induction, levels of galactose (and, therefore, protein) are identified at which comparable levels of reporter are produced (Resnick and Inga, 2003) . (d) Quantitative assessment of p53 transactivation capacity in vivo. A luciferase reporter assay is used to assess the ability of wild-type or mutant p53 to transactivate from specific REs in yeast. The quantitative luciferase assay provides 'kinetics' of transactivation for wild-type and mutant p53 over a range of p53 expression levels, from basal to high levels, in logarithmically growing cells. As presented, transactivation by wild-type p53 can differ considerably between REs. Furthermore, the effect of specific mutations on the ability of p53 to transactivate from different REs can be readily assessed. Tokino et al., 1994; Wang et al., 1995; Inga et al., 2002b; Tomso et al., 2005; Wei et al., 2006) . However, we have found that a consensus sequence can retain limited function with larger separations between the 10 bp dimers in mammalian cells (Menendez et al. in preparation) . Moreover, even a halfsite can provide low level p53-mediated transactivation of a gene (Menendez et al., 2006b ) (discussed below). Importantly, once a consensus sequence was established, the sequence could be used to determine, if the transcriptional responsiveness to the stress of various genes was mediated through direct p53 regulation, indicated by p53 sequences associated with the genes in question, or through downstream targets (Wang et al., 2001; Hoh et al., 2002; Weinberg et al., 2005) . Although these approaches have been useful for identifying potential sequences that may interact with p53, they do not provide for the in vivo assessment of relative transactivation capability from different REs. Sequence differences and strength of binding have been invoked to explain possible differences in transactivation of groups of genes subject to direct control by p53, as for the case of cell-cycle control versus apoptotic genes (ResnickSilverman et al., 1998; Vousden, 2000; Zhao et al., 2000; Kannan et al., 2001; Qian et al., 2002; Lim et al., 2006) .
Relationship between target sequence and transactivation for wild-type p53
Although p53 must bind a RE to effect transactivation, the relationship between binding and the actual level of transcription of a target gene can be determined by many more factors including other co-activators, as noted above, as well as post-translational modifications (Espinosa and Emerson, 2001; Szak et al., 2001; Kaeser and Iggo, 2002; Espinosa et al., 2003) . Even if p53 is bound to a RE in the absence of stress, additional proteins may determine the extent of transactivation (Espinosa et al., 2003) . Also, as the levels of p53 can vary in response to stress and between cell types, the extent of transactivation in a simple protein-DNAbinding model might be expected to be determined by binding (K d ) and the amount of activated p53 that is available, after accounting for other factors. There are alternative possibilities to how p53 might act including, for instance, a simple off-on switch that is dependent only on the presence of some level of p53 (Vousden, 2000; Kaeser and Iggo, 2002) .
To address strictly the relationship between sequence and p53 transactivation, in vivo, isogenic systems are required in which the only variables are the level of p53 and the target sequence, a situation difficult to attain in mammalian cells. For example, experiments relying on transient transfection do not provide the control of p53 or the number of copies of reporter plasmids with upstream target sequence. This led to the development of a surrogate isogenic system based in yeast (which has no p53 gene) that provides strict control of p53 levels along with a single integrated copy of a target RE upstream of a reporter, as diagrammed in Figure 1b (Inga et al., 2002b; Resnick and Inga, 2003) . The system extends previous yeast-based approaches (Figure 1a ) that were developed to address the functionality of p53 mutants (Ishioka et al., 1993; Flaman et al., 1995; Brachmann et al., 1996; Campomenosi et al., 2001) . Briefly, the p53 coding sequence is placed under the control of a GAL1 promoter, which provides for rheostatable control of p53 expression through variation in the amount of galactose in the medium. Transcription of the p53 complementary DNA is dependent on the activation of GAL1 promoter by GAL4 (Johnston, 1987; Lohr et al., 1995) . Gal4 binds to the upstream activation sequence (UAS) of GAL1. In the absence of galactose, Gal80 interacts with Gal4 inhibiting its ability to function as an activator, although it may bind the UAS. Addition of galactose leads to Gal3 inhibition of the Gal8-Gal4 interaction, allowing Gal4 to stimulate the activation of its target genes. Glucose prevents GAL1 expression through catabolite repression mechanism. There is a basal level of p53 expression on raffinose, and p53 expression can be increased several 100-fold in proportion to the amount of galactose added. p53 dependent transactivation of a reporter gene from a RE can be detected with color reporters using colony plate assays (Figure 1c) . Efficiencies of transactivation can thus be compared across different levels of p53. A luciferase-based assay has provided the opportunity to address transactivation in cultures of logarithmically growing cells at very low levels of p53 (Figure 1b and d ). An additional distinct advantage of yeast is the opportunity to rapidly modify in vivo either the target REs or to create mutant p53 coding sequences utilizing a highly efficient recombination-based system, known as delitto-perfetto (Italian for 'perfect murder') that targets desired changes with oligonucleotides (Storici et al., 2001 (Storici et al., , 2003 Storici and Resnick, 2006) .
The combination of a rheostatable system with over 50 REs, most of which are found in human cells, has revealed a several 100-fold variation in the ability of putative REs to support transactivation by p53 (Inga et al., 2002b) . For a few of these REs, available data from competitive gel shift assays supported our results (Freeman et al., 1994; Wang et al., 1995; Resnick-Silverman et al., 1998; Thornborrow et al., 2002) . These findings contrast with results obtained with PWM algorithms that would predict comparable activity between the REs. More recently, a sophisticated in vitro quantitative analysis of sequencespecific p53-binding to DNA revealed large differences in affinities for various REs (Weinberg et al., 2005) .
When all other factors are kept equal, the yeast-based results suggest a wide range potential for transactivation that is determined by the RE sequence and level of protein. Thus, for any level of p53 protein, there is an intrinsic capability for the transactivation responsiveness of each RE. Although other factors are clearly important, these results have been interpreted in terms of a model based on a piano (Figure 2 ) (Resnick and Inga, 2003) . The 'hand' is p53 that can press the various 'keys' (i.e., genes) with different intensities. As a result, a 'chord' is created from the various genes being turned on to various extents that results in a 'sound,' the biological response or phenotype.
Relationship between sequence and transactivation for altered-function p53 mutants
Most cancer-associated p53 alterations are due to missense mutations located in the DNA-binding domain (Olivier et al., 2002; Hamroun et al., 2006) (http:// p53.bii.a-star.edu.sg/index.php). This suggests that the DNA-binding and consequent transactivation capability of p53 are especially important in preventing cancer, which is consistent with the various categories of genes controlled by p53 (Vogelstein et al., 2000; Levine et al., 2006) . However, many p53 mutations do not eliminate transactivation capability (Kato et al., 2003; Hamroun et al., 2006) . In an exhaustive yeast-based study that investigated nearly all possible single base substitution mutations, approximately 30% of the mutant proteins retained function towards at least one RE, consistent with other yeast-based studies (Kato et al., 2003; Shiraishi et al., 2004) . These altered-function mutants differ from the 'gain-of-function' mutants described in human cells, which have lost sequence-specific transactivation capability. The gain-of-function mutants are able to influence the transactivation of other genes through RE-independent mechanisms, such as proteinprotein interactions with large protein complexes that are recruited to specific promoters by other sequencespecific transcription factors (Blandino et al., 1999; Di Agostino et al., 2006) , or alternatively the mutant p53s are able to impact on chromatin metabolism (Deppert et al., 2000; Rubbi and Milner, 2003) .
Altered-function mutants have been examined extensively with the rheostatable yeast-based system (Resnick and Inga, 2003) . Even though many of the mutants simply result in an overall dampening of transactivation (i.e., reduction in the 'volume' of the chord in Figure 2) , surprisingly, several were change-in-spectrum such that new-sounding chords were produced, where intensities of individual keys were changed and some keys were even lost from the chord. The nature of the chord would be determined in part by the amount of p53 available, that is, the strength of the hand. Among the change-inspectrum mutants were those that resulted in much stronger transactivation than wild-type at low p53 levels . These super-trans mutants might be expected to dramatically affect the relevant biological pathways. An interesting category of mutants was revealed that resulted in cell killing when expressed at other than low levels . Not only were these mutants toxic, they were also shown to exhibit greatly increased transactivation towards some REs when expressed at low p53 levels. A UVinduced skin cancer hot spot mutation T122L (corresponds to the T125 position in humans) was identified in repair-deficient mice that were also heterozygous for p53 (Reis et al., 2000) . This mutation resulted in a change-in-spectrum phenotype towards many REs in yeast Figure 2 A piano model to describe the master regulator p53 and mutants transactivation of target genes. As described in Resnick and Inga (2003) , a master regulatory gene such as p53 directly controls the expression of many genes, similar to hands playing keys on a piano (bottom of figure) . The p53 piano has many 'keys' corresponding to the directly targeted genes, and it is played by the p53 'hand' where the fingers interact directly with promoter REs. As a result, a 'chord' is created such that each note or key may be played with a different intensity (i.e., level of transactivation). For p53 mutants that retain partial function or have altered DNA-binding specificity, the p53 'hand' can have some fingers that are stronger (bold type) or weaker (smaller and lighter type) and some inactive fingers that do not strike keys. In addition it is possible that new keys will be played. The resulting 'sounds' played by wild-type and mutant p53 hands correspond to the cellular phenotype. In the case of p53 mutants, some of these changes can result in new chords and sounds with novel biological consequences, for example, different sensitivities to DNA-damaging-agents resulting from expression of wild-type versus the T125R mutant (top panel) (Menendez et al., 2006a) . (This figure is adapted from (Resnick and Inga, 2003) ).
Changing the p53 master regulatory network D Menendez et al (Inga et al., 2002a) , suggesting that the altered p53 chord could be highly selected under certain circumstances. The piano analogy for transactivation was found to apply to the expression of endogenous target genes when certain p53 mutants were expressed at biologically meaningful levels in human cells (see example in Figure 2 ) (Menendez et al., 2006a) . To test directly the piano interpretation of p53 change-in-spectrum mutants, several were examined in human osteosarcoma SaOS2 (p53-/-) cells in a tetracycline (Tet) off-on regulatable system. Wild-type and various p53 mutants were placed under Tet control and integrated into SaOS2 cells. Individual clones were selected such that the level of expression attainable was comparable with that measured following UV-irradiation of other cell lines containing a functional p53 gene. Following induction, each of the mutants exhibited unique induction patterns for the target genes examined. Interestingly, under these conditions the level of p53-induced transcription of the endogenous target genes reflected the extent of binding, as measured by ChIP at promoter regions containing REs, which suggests that under the off-on conditions for p53 induction used, there is a direct relationship between promoter occupancy and transactivation. In this case, differences in transactivation capability towards the various REs appear to be due to the ability of the proteins to bind rather than in the capability for transcription once bound.
When a p53-inducing genotoxic stress (UVC-irradiation) was applied to the cells, p53 protein levels increased. This increase was associated with the appearance of post-translational modifications that resulted in higher p53 protein stability and proportionally higher occupancy levels. Overall, those results suggest that allosteric modification of p53 protein does not provide a major level of regulation of p53 activities except as expected when more p53 is available, consistent with previous reports (Espinosa and Emerson, 2001; Kaeser and Iggo, 2002) .
The changes in the transactivation of p53 target genes induced by some change-in-spectrum mutants resulted in a substantial alteration of cellular responses to ionizing and UV-irradiation in terms of clonal survival and apoptosis (Menendez et al., 2006a) . For example, the T125R mutation reversed the sensitivities to these two agents (Figure 2 ) as compared with wild-type p53. Thus, the 'chord' of genes played and the intensities were changed so that the resulting biological responsethe 'sound' -was altered. The finding that a single p53 mutation can dramatically alter the pattern of genes induced as well as their levels has several implications for cancer. For example, the biological consequences could depend on the specific altered-function mutation, and this might influence opportunities for treatment.
Evolution of the p53 network
In a broader sense, the results with change-in-spectrum single mutants as well as variation in the responsiveness of REs to p53 transactivation suggest mechanisms of selection in the evolution of master regulatory networks. This concept is supported by findings with the Spalax blind mole rat (Ashur-Fabian et al., 2004; Avivi et al., 2005) , which lives underground and is subjected to hypoxic conditions. It appears to have uniquely adapted to the p53-inducing conditions of life with less oxygen by two lysine changes at the conserved arginine codons corresponding to R174 and R209 in human p53. The p53 protein alignment from 44 species and functional analysis of the mutated proteins suggested that the R174K is an alteredfunction p53 mutation, also found in human tumors. This mutant p53 protein apparently results in less induction of the apoptosis set of genes and this could contribute to the adaptation of the species to a hypoxic environment.
A proline to arginine polymorphic variant at p53 codon 72 is another example of a p53 variant, which may represent a genetic source of adaptive phenotypic diversification. The two alleles differ in the potential for protein-protein interactions and induction of apoptosis and the allelic status could impact the outcome of viral infections, the risk of developing cancer as well as impact the progression of the disease (Storey et al., 1998; Thomas et al., 1999; Bergamaschi et al., 2003; Bergamaschi et al., 2006) (for a summary of cancer risk-association studies see http://p53.bii.a-star.edu.sg/aboutp53/snps/snpdetail. php?geneid ¼ X54156&snppos ¼ 12139). Interestingly, the allele frequency broadly varies in the human population and follows a geographical gradient.
Evolution can also occur through changes in the target REs of the p53 master regulatory network. Along this line, the DDB2 gene involved in global repair of UV-induced damage is not responsive to direct p53 transactivation in mice unlike the situation in humans (Tan and Chu, 2002) . A closer examination of the DDB2 gene indicates that unlike for humans, there is not a functional p53 target RE, consistent with lack of p53-binding at the mouse promoter. As a result, this could result in mice being much more sensitive to UV-induced skin cancers in areas of exposure.
There are now several examples of human diversity in the p53 network that are due to changes in REs (Contente et al., 2002; Tomso et al., 2005) . In one case, a single nucleotide polymorphism (SNP) in the promoter region of the MDM2 enhances the opportunity for binding by the transcription factor SP1 and results in higher basal levels of the MDM2 protein with a consequent reduction in p53 level/functionality (Bond et al., 2004; Arva et al., 2005) . Several studies have examined the impact of this SNP (known as SNP309) on the risk of developing cancers. Although an initial report showed a clear effect on the age of onset for familial as well as sporadic sarcomas (Bond et al., 2004) , other studies produced conflicting results on the association between SNP status and cancer risk. Recently, it was recognized that the impact of this regulatory SNP is influenced by estrogen receptors (ER) (via a nearby target RE). When ER status and hormonal levels were taken into account, SNP309 resulted in higher risk or aggressiveness of colon and breast cancer (Bond et al., 2006a, b) .
Human diversity in target REs has been explored directly using an approach that combines bioinformatics Changing the p53 master regulatory network D Menendez et al and functional analysis (Tomso et al., 2005) . Reasoning that single base changes in putative p53 responsive REs might be expected to impact significantly the potential for transactivation, an extensive SNP database was perused for pairs of alleles, where one might be expected to be a well-functioning RE for p53-transactivation and the other would be a poor p53 target. For example, alleles that differed by C or G in the central CATG sequence would be expected to have a marked effect on transactivation function. The search focused on a region 5 kb from the start site of a gene, the region of the vast majority of p53 target REs. Among the many candidates, over 40 pairs of such SNP alleles were identified (Tomso et al., 2005) . There were no SNP pairs identified for any of the established human p53 REs. Most of the newly discovered putative p53 REs had not been reported earlier. Several of the pairs of REs were then functionally compared through transactivation analysis in yeast and in human cells (Figure 3 ). For the latter, the RE alleles were placed in plasmids upstream of reporters and transfected along with p53-expressing plasmids into SaOS2 cells. In all cases, the predicted stronger allele always yielded greater transactivation than the predicted weaker allele for the eight pairs of alleles tested in yeast or human cells (Figure 3 ). For example, the SNP alleles in the promoter of the ADAR2 adenine deaminase gene (GGACAAGTTg-AAACTT(G/A)CaC) and Toll-like receptor gene (TLR8) (AGGCAAGaTg-AAACAT(G/A) TCa) exhibited dramatic differences in p53 transactivation.
These findings of SNP variations in REs demonstrate that there may be considerable diversity between humans in terms of responsiveness to wild type and even altered-function, cancer-associated p53 mutants (Menendez and Resnick, in preparation) . In terms of the piano model (Figure 2) , this would correspond to variations in the keys that are available for playing on different individual pianos.
The rules of engagement are not so ELEMENTary, my dear Mr Watson
As discussed above, for many years the metric for identifying p53 target REs has been a consensus sequence consisting of two RRRCWWGYYY decamers separated by a small number of bases. Figure 3 Modulation of the p53-transactivation network by SNPs in p53-REs that alter p53-transactivation capacity. The ability of pairs of SNP-RE alleles to support p53 transactivation was determined under isogenic conditions in yeast and in human SaOS2 (p53À/À) cells (adapted from (Tomso et al., 2005) ). The REs are located upstream from minimal promoters and luciferase reporter genes. (a) Transactivation capacity in yeast. Luciferase activity for the predicted strong and predicted weak SNP RE allele is presented as relative induction between p53-expressing cells and control cells lacking p53. (b) Transactivation capacity in mammalian cells. p53-null SaOS2 cells were transiently co-transfected with CMV vectors containing p53 and the luciferase reporter constructs that contains one of the pair of RE alleles. Luciferase activity was measured relative to the empty pGL3-promoter vector in the absence or presence of p53. The nucleotide beneath each bar corresponds to the specific SNP allele examined. The AIP1 and P21-5' p53 REs served as positive controls.
Changing the p53 master regulatory network D Menendez et al
Evaluation of the ability of p53 to transactivate from a RE with yeast-based assays has demonstrated that the specific sequence of the p53 RE can contribute greatly to the level of transactivation obtained by wild-type p53. Additionally, there is an increasing need to examine further if the organization of the RE, in terms of spacer distance and the requirement for the presence of four quarter-sites alters the ability of p53 to function from a specific sequence. Examination of many REs through functional assays to empirically obtain the rules of transactivation has indicated that p53 transactivation could also be accomplished with a 3/4 site (i.e., a halfsite with an adjacent quarter site) based on results with the proliferating-cell nuclear antigen promoter gene which contains the sequence GAACAAGTCCGGG CATaTgT. The p53 protein can strongly interact with this sequence in vitro (Weinberg et al., 2005) and lead to modest induction in the yeast-based system (Jordan and Resnick, in preparation). In addition, functional studies have demonstrated that spacer size between decamer half-sites can impact the ability of p53 to transactivate from a RE in yeast and human cells (unpublished) .
It was recently reported that even a putative half-site can provide good responsiveness to p53 (Menendez et al., 2006b) . The promoter of the human Flt1 gene, which codes for the VEGF receptor 1, a component of the VEGF pathway, was examined for possible SNPs that might affect its regulation. A SNP was identified (C/T) that resulted in one allele having a consensus p53 half-site: GGACA(c/T)GCTC. Immediately beyond this half-site was the sequence (CCCCTG)GGACcTGagC that was poorly related to a p53 consensus. Unlike the C-allele, the T-allele was able to bind p53 and functioned in p53-induced transactivation. Subsequent investigations have shown that the p53 T-allele half-site binds p53 and supports a small amount of p53 transactivation on its own, although it binds p53 (Menendez et al., in press) . Surprisingly, the presence of a nearby ER target RE enabled p53 transactivation.
These findings with the Flt1 promoter demonstrate that a much smaller RE sequence is needed for p53 to function in the genome provided that other co-transactivating sequences are available. Furthermore, the Flt1-T allele merges three important biological pathways: stress (p53), hormonal responses (ER), and angiogenesis (VEGF receptor Flt1). Importantly, these findings suggest that master regulatory partial target REs might provide a genetically wired means for crosstalk between pathways.
Implications
The ELEMENTary components of master regulatory networks are the REs along with the sequence-specific TFs. Differences in RE sequences, changes in p53 levels and post-translational modifications, along with amino acid alterations in p53 provide a large matrix, in which the expression network of target and downstream genes can be varied in the context of disease states, inter-individual genetic variability (e.g., SNPs) or species-specific evolutionary separation. Considering the central role that p53 plays in preventing tumorigenesis, understanding p53 biology and defining new components and interactions within its network will be valuable in cancer prevention. Along these lines, an emerging issue relates to the health impact of RE sequence variation within the human population as well as the consequences of somatically acquired or inherited altered-function p53 mutants. There are limited studies where a functional classification that distinguishes altered versus loss-of-function p53 mutants was adopted to query clinical data on cancer likelihood and outcomes. For breast cancer, functional classification of p53 does not appear to add prognostic value to the knowledge about p53 mutant status (Olivier et al., 2006) . It is interesting that several p53 mutations associated with breast cancer, particularly in BRCA1-related cases, appear wild-type for transactivation under normal expression conditions, but some are clearly different from wild type when expressed at low levels (Resnick and Inga, 2003) . For germinal p53 mutations resulting in familial cancer proneness, complete loss of function, as compared with altered function, appeared to be associated with earlier cancer onset and more severe clinical manifestations (Fronza et al., submitted) .
The importance of sequence-specific binding in p53 transactivation versus the role of other factors continues to be a fundamental issue in understanding the action of TFs. Beyond TFs there is a complex interplay between stress-signal transducers, their regulated TFs and chromatin states at target promoters. In addition, there is a plethora of induced epigenetic changes that can impact the outcome of protein-protein interactions between TFs, cofactors, mediators and basal transcriptional components (Ito et al., 1999; Espinosa et al., 2003; Wallberg et al., 2003; An et al., 2004; Minsky and Oren, 2004; Zhang et al., 2005) . Although the recruitment of p53 at the target RE(s) is a necessary step, it may not be sufficient for changing transcription rates, unless specific cofactors are recruited and/or other cis-acting factors are concertedly activated (Espinosa et al., 2003; Gomes et al., 2006) . Formally, the outcome of transcriptional modulation elicited by a sequence-specific TF could be largely dictated by the cofactor(s) tethered by the TF at the site.
Along this line, an important question that needs to be further examined is to what extent RE sequence can act as an allosteric modifier of promoter bound TFs, impacting the assembly of higher order transcriptional complexes (Lefstin and Yamamoto, 1998) . Based on biochemical and biophysical characterization, several models for p53 action have been suggested that focused on the ability of p53 to bind specific genomic sequences resulting in the transactivation of adjacent genes (Prives and Hall, 1999; Vogelstein et al., 2000) . Results have supported p53-induced, RE-dependent conformational changes that could be related to differences in binding affinities and provided an initial framework for explaining transactivation specificity. However, a critical issue that could not be properly addressed experimentally was the impact of RE sequence on the quaternary structure of p53-DNA complexes, namely the possibility of conformational variation of DNA-bound p53 tetramers, which could be an underlying source of diversity in transcriptional outcomes. For nearly 12 years, there has been only one crystal structure of human p53 bound to DNA (Cho et al., 1994) . However, because the p53 used was restricted to monomers, the more general nature of p53-RE interactions could not be addressed. Recently, Kitayner et al. (2006) reported the structure of three p53:DNA crystals obtained with the p53-DNA binding domain and different half-site RE sequences (GGA CATGTCC, AGGCATGCCT; GGGCATGCCC plus one flanking base). In every case, four p53 molecules self-assembled on two DNA molecules resulting in a p53 tetramer consisting in a dimer of dimers. Differential p53-DNA binding affinity could be related to sequencespecific variations in the protein-DNA contact geometry. The structures also predicted that the four transactivation domains in the p53 amino terminus would have a common orientation with respect to the tetramer bound to DNA, which may facilitate cooperative recruitment of co-factors. These findings provide a new structural understanding of p53 binding to REs and they are likely to form the basis for addressing the large differences in transactivation from various REs, the consequences of mutations in p53, and the mechanisms for searching REs among nonspecific genomic DNA (Hupp and Lane, 1994; Ahn and Prives, 2001; Espinosa and Emerson, 2001; McKinney et al., 2004) .
Our finding that half-site p53 REs can provide responsiveness to p53 has many implications and demonstrates that the p53 master regulatory network is even more complex and larger than envisioned based on the standard 20 base consensus sequence. In light of the recent structural characterizations discussed above, it will be interesting to understand how p53 can transactivate from a half-site or a 3/4 site. In addition, the size and complexity of the p53 master regulatory network may be much greater than envisaged based on the standard 20 base consensus sequence. The results with a half-site raises the possibility of a multifactorial synergistic interconnection of master regulators involving partial or even nonfunctional REs. Along this line, although wholegenome ChIP analysis (Wei et al., 2006) , has provided opportunities to identify strong p53-RE interactions, there are likely to be many more that will require even more sensitive methods for detection. In addition to roles in gene regulation, the sequence-specific interactions with partial sites might have other functions, including the suggested possibility of 'chromatin relaxation' in order to facilitate DNA repair (Rubbi and Milner, 2003) .
In its role as a master transcriptional regulator, p53 also appears able to trans-repress genes (Ho and Benchimol, 2003) including those affecting signaling pathways such as cell proliferation (cyclin B, RNA polymerase I, c-myc), apoptosis (bcl-2, survivin) and cytoskeleton organization (stathmin and map4) Xu and el-Gewely, 2001; Ho and Benchimol, 2003) . In general, the mechanism(s) of repression is often unclear and may not be dependent on site-specific DNA-binding activity (Zhai and Comai, 2000; Koumenis et al., 2001; Ho et al., 2005) . For example, the responsiveness of some genes to p53 can be indirect in that target genes (transactivated or transrepressed) might be transcription factors, which then affect downstream responses to p53 signaling (Xu and El-Gewely, 2003) . Clear mechanisms of p53-dependent repression have been identified in the association between p53 and histone deacetylases and other chromatin remodeling co-factors, as well as co-repressors Ho and Benchimol, 2003) . Although sites are suggested, there is no clearly identified consensus p53-binding site within repressed promoters. How these sites differ from those in transactivated promoters has only begun to be elucidated (May and May, 1999; Johnson et al., 2001; Hoffman et al., 2002) . Alternatively, bound p53 may impede the binding of other transcriptional activators, as is the case of the DNA polymerase delta gene (Li and Lee, 2001 ) and the antiapoptotic gene survivin (Hoffman et al., 2002) . Future studies are likely to further elucidate the consensus sites at which p53 could have a repressive effect as well as structure-function relationships, based on recent crystal structures (Kitayner et al., 2006) .
The identification of the complete repertoire of p53-regulated genes is still far from complete (Miled et al., 2005; Wei et al., 2006) . In recent years, a variety of genomic techniques (microarrays, SAGE, ChIP, EMSA) have been utilized to identify p53-regulated target genes. Gene expression has been examined in various cell types, with several DNA-damaging-agents that lead to p53 activation, or simply by restoring the p53 expression in parental p53 null cells (el-Deiry, 1998; Yu et al., 1999; Zhao et al., 2000; Wang et al., 2001; Xu and El-Gewely, 2003; O'Farrell et al., 2004) . However, in most studies it has been difficult to distinguish between direct and indirect transactivation effects of p53 or mutants. Approaches utilizing isogenic analysis and variation in levels of p53 expression can resolve some of these issues.
Finally, the approaches for characterizing wild-type p53 and mutant proteins using variable expression and interactions with REs under isogenic conditions can be applied to other sequence-specific TFs. For example, the NKX2-5 protein is required for human heart development. Using the yeast-based system, single and multiple somatic mutations identified in congenital heart disease have been shown to result in altered abilities to transactivate from NKX2-5 target REs . The findings with p53 and NKX2-5, as well as other genes currently under study (Inga and Resnick, in preparation) , also support the view that sequencespecific master regulators could be master genes of diversity, where single amino acid changes can greatly alter the target and downstream genes included in master regulatory networks as found for some cancerassociated p53 mutations (Resnick and Inga, 2003) .
